A comprehensive approach to Parkinson's disease. How to manage fluctuating motor and nonmotor symptoms (Q36567733)

15 August 2017

1 reference

title

A comprehensive approach to Parkinson's disease. How to manage fluctuating motor and nonmotor symptoms (English)

1 reference

15 August 2017

Stephen Brunton

1

1 reference

PubMed ID

16913648

15 August 2017

language of work or name

English

0 references

publication date

1 June 2006

1 reference

15 August 2017

Postgraduate Medicine

1 reference

15 August 2017

119

1 reference

15 August 2017

1

1 reference

15 August 2017

55-64

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2006.06.1643

15 August 2017

1 reference

Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2006.06.1643

Environmental risk factors and Parkinson's disease: a metaanalysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2006.06.1643

Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2006.06.1643

Treatment of depression in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2006.06.1643

Treatment interventions for Parkinson's disease: an evidence based assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2006.06.1643

Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2006.06.1643

Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2006.06.1643

Rapid treatment of "wearing off" in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2006.06.1643

Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2006.06.1643

Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2006.06.1643

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2006.06.1643

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2006.06.1643

Levodopa and the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2006.06.1643

Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2006.06.1643

Rivastigmine for dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2006.06.1643

Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2006.06.1643

21 January 2018

Identifiers

DOI

10.3810/PGM.2006.06.1643

1 reference

15 August 2017

1 reference

PubMed ID

16913648